Biocon partners with CytoSorbents to market CytoSorb

Biocon and CytoSorbents Corporation, based in the US, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb, a novel therapy for the management of sepsis.

September 13, 2013 / 11:58 IST

26 Aug, 2025 12:21

Volume

Todays L/H

Biocon Ltd has informed BSE regarding a Press Release dated September 13, 2013 titled "Biocon Partners with CytoSorbents to Market CytoSorb®-A 'First-in-Class' Therapy for Sepsis Management".

Biocon and CytoSorbents Corporation, based in the US, announced today, World Sepsis Day, that they have entered into a strategic partnership with an initial distribution agreement for India and select emerging markets, under which Biocon will have the exclusive commercialization rights for CytoSorb, a novel therapy for the management of sepsis.Source : BSE

Read all announcements in Biocon

first published: Sep 13, 2013 11:58 am

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

Al Edge Newsletter On Saturdays

Find the best of Al News in one place, specially curated for you every weekend.
MC Tech 3 Newsletter Daily-Weekdays

Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347